Six in Ten Cancer Survivors With Pain Live With High-Impact Chronic Pain, Study Finds

Chronic pain is one of the most stubborn legacies of modern cancer care, and a new Danish study suggests it is far more disabling than many clinicians appreciate. Researchers from Odense University Hospital and the Danish Knowledge Centre for Rehabilitation and Palliative Care (REHPA) applied a structured classification tool, the Graded Chronic Pain Scale-Revised (GCPS-R), to cancer survivors attending residential rehabilitation courses. Their findings, published in Supportive Care in Cancer, reveal that 61 percent of survivors reporting cancer-related pain met the criteria for high-impact chronic pain, a level of pain that substantially interferes with daily life. The result underscores a growing concern in survivorship research: pain is not merely present in this population, it is often severe enough to reshape how people live, work, and cope long after treatment ends.

The study matters because chronic cancer-related pain is both common and chronically under-recognized. Previous research has estimated that chronic pain affects between 28 and 47 percent of cancer survivors, and US population-based data have shown a prevalence of 31 percent among people with a cancer history compared with 16 percent among those without one. In a US survey of more than 4,500 survivors, 36 percent reported chronic pain, and nearly half of those were categorized as having high-impact chronic pain. Yet routine assessment of pain characteristics is not standard practice in many oncology settings, which means the patients who most need intensive, interdisciplinary support can slip through the cracks. The Danish team set out to test whether a brief, validated questionnaire could systematically separate survivors whose pain is a nuisance from those whose pain is life-altering.

The GCPS-R is a six-item self-administered instrument that classifies chronic pain, defined as pain on most days or every day during the past three months, into hierarchical grades: mild chronic pain, bothersome chronic pain, and high-impact chronic pain. High-impact chronic pain is defined as pain persisting for at least three months that limits life activities or work on most days or every day. Among participants with chronic pain who do not meet that threshold, the scale uses a three-item Pain, Enjoyment and General Activities score with a cut-off of 12 or higher to distinguish bothersome from mild pain. Because the tool was originally developed for chronic non-cancer pain, its application to a cancer population is relatively novel, and the researchers wanted to know whether it could carve out clinically meaningful subgroups among survivors.

The cohort consisted of adults attending REHPA’s structured rehabilitation courses between March 2022 and February 2025. These courses follow a distinctive format: an initial five-day residential stay, seven to ten weeks at home, and a final two-day follow-up. Before arrival, participants completed a routine screening questionnaire covering quality of life, psychological distress, fatigue, sleep, and pain. Those meeting predefined pain criteria, such as average pain intensity of at least 4 on a 0-to-10 numeric scale over the past two days, or pain interfering substantially with daily activities, were invited to complete a supplementary pain-specific module. Of 877 course participants, 375 met the pain criteria, and 300 completed the supplementary module. After excluding respondents with incomplete data or without chronic pain by the GCPS-R definition, the final analytical sample comprised 270 survivors with chronic pain.

The underlying diagnoses reflected the realities of rehabilitation referrals: 58 percent had breast cancer, 9 percent gastrointestinal cancer, and 9 percent hematological cancers, mainly multiple myeloma, with the remainder spread across other diagnoses. When the GCPS-R was applied, 13 percent were classified as having mild chronic pain, 26 percent bothersome chronic pain, and 61 percent high-impact chronic pain. More than half of the entire cohort, 54.8 percent, reported pain lasting more than a year, and long duration was most common in the high-impact group, where 62.7 percent had lived with pain for over a year, compared with 44.3 percent of the bothersome group and 38.2 percent of the mild group, a statistically significant difference.

The gradient across grades was striking and internally consistent. Survivors with high-impact pain reported significantly higher pain intensity and pain-related disability, more widespread pain, higher depression scores, and lower self-rated health and quality of life than those in the bothersome and mild groups, with all comparisons reaching statistical significance. Mean pain intensity corresponded to moderate-to-severe levels in the high-impact group, moderate levels in the bothersome group, and low levels in the mild group. Pain catastrophizing, measured with a single validated item from the Pain Catastrophizing Scale asking whether pain feels terrible and never-ending, and disability scores on the Pain Disability Index were also significantly elevated in the high-impact and bothersome groups relative to the mild group. Notably, the three groups were similar in age, sex, marital status, education, and health behaviors, suggesting that the classification was capturing differences in pain impact rather than demographic confounding.

Perhaps the most provocative part of the study was its exploratory comparison with non-cancer pain patients. The researchers matched 166 cancer survivors with high-impact chronic pain to 498 patients with non-cancer high-impact chronic pain drawn from the Danish PainData Registry, using stratified random sampling in a 1-to-3 ratio within ten-year age bands and matching on age and sex. The non-cancer patients had typically endured pain far longer: among those with available data, 94.2 percent had pain lasting more than a year, with a median duration of 7.6 years and a mean of 11.1 years. Despite meeting the same impact criteria, the two groups looked different on several dimensions.

The non-cancer group reported significantly higher pain intensity, greater pain-related disability, more depressive symptoms, more pain catastrophizing, larger pain distribution, and lower self-rated health, with effect sizes ranging from small to large, including a large difference in disability. Anxiety scores, however, were statistically indistinguishable between the groups. The most intriguing finding concerned widespread pain, defined by the American College of Rheumatology 1990 criteria as pain on both sides of the body, above and below the waist, and in the axial skeleton. Although the non-cancer patients reported more pain areas overall, cancer survivors were at least as likely to meet the widespread pain criteria, with roughly two-thirds of the high-impact cancer group fulfilling them. The authors suggest this pattern may reflect the spatial signature of treatment-related pain: chemotherapy-induced peripheral neuropathy often affects both upper and lower extremities, and hormonal therapies such as aromatase inhibitors and surgical late effects are associated with persistent, diffuse pain.

These differences also map onto evolving diagnostic frameworks. Under the ICD-11 classification, chronic cancer-related pain is categorized as chronic secondary pain, attributable to a known disease or its treatment, whereas many non-cancer pain patients fall under chronic primary pain, where pain itself is the principal problem and often lacks a clear biomedical cause. The authors argue that such typological distinctions may shape how patients interpret symptoms and cope with them, and that high-impact pain is a heterogeneous construct whose clinical presentation and drivers differ across populations. In practical terms, the findings suggest that cancer survivors with high-impact pain may need tailored, interdisciplinary interventions that go beyond standard biomedical approaches, and that access to cancer-specific pain expertise deserves strengthening.

The study has clear limitations that temper its conclusions. It drew on a selected population of survivors who actively applied for rehabilitation at a single center, potentially biasing the sample toward more resourceful or motivated individuals, and women were heavily overrepresented. Detailed clinical variables such as disease stage, time since diagnosis, and specific treatments were not systematically available, pain was self-reported as cancer-related without clinical verification, and some participants with pain lasting less than three months were nonetheless classified as having chronic pain. Still, the prospective design, relatively large sample, low missing-data rates, and the well-characterized matched comparison group lend the findings weight. The core message is hard to ignore: when cancer survivors report pain, more than half may be living with pain severe enough to disrupt daily life, and a six-item questionnaire can identify them. Systematic assessment of pain impact, not just its presence, could become a simple, powerful step toward getting the right survivors the right care.

Subject of Research: Classification of high-impact chronic cancer-related pain among cancer survivors using the Graded Chronic Pain Scale-Revised

Article Title: Identification of high-impact chronic pain among cancer survivors: a cross-sectional study using the Graded Chronic Pain Scale framework

Article References: Jespersen, J. R., Vaegter, H. B., Elnegaard, C. M., & Jarlbaek, L. (2026). Identification of high-impact chronic pain among cancer survivors: a cross-sectional study using the Graded Chronic Pain Scale framework. Supportive Care in Cancer, 34(10), Article 961. https://doi.org/10.1007/s00520-026-11190-z

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11190-z

Keywords: cancer survivors, chronic pain, high-impact chronic pain, Graded Chronic Pain Scale-Revised, pain classification, cancer rehabilitation, pain disability, psychological distress, widespread pain, ICD-11, interdisciplinary pain care, supportive care